Logo image of NBTX

NANOBIOTIX SA - ADR (NBTX) Stock Fundamental Analysis

USA - NASDAQ:NBTX - US63009J1079 - ADR

29.91 USD
+2.61 (+9.56%)
Last: 10/9/2025, 9:29:58 PM
28.36 USD
-1.55 (-5.18%)
Pre-Market: 10/10/2025, 4:58:10 AM
Fundamental Rating

1

NBTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. Both the profitability and financial health of NBTX have multiple concerns. NBTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NBTX had negative earnings in the past year.
NBTX had a negative operating cash flow in the past year.
NBTX had negative earnings in each of the past 5 years.
In the past 5 years NBTX always reported negative operating cash flow.
NBTX Yearly Net Income VS EBIT VS OCF VS FCFNBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of NBTX (-114.32%) is worse than 78.36% of its industry peers.
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBTX Yearly ROA, ROE, ROICNBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

NBTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBTX Yearly Profit, Operating, Gross MarginsNBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

0

2. Health

2.1 Basic Checks

NBTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NBTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NBTX has more shares outstanding
Compared to 1 year ago, NBTX has a worse debt to assets ratio.
NBTX Yearly Shares OutstandingNBTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NBTX Yearly Total Debt VS Total AssetsNBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

NBTX has an Altman-Z score of -9.02. This is a bad value and indicates that NBTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.02, NBTX is not doing good in the industry: 70.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.02
ROIC/WACCN/A
WACC7.85%
NBTX Yearly LT Debt VS Equity VS FCFNBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 0.63 indicates that NBTX may have some problems paying its short term obligations.
NBTX has a worse Current ratio (0.63) than 91.79% of its industry peers.
A Quick Ratio of 0.63 indicates that NBTX may have some problems paying its short term obligations.
NBTX has a Quick ratio of 0.63. This is amonst the worse of the industry: NBTX underperforms 91.04% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
NBTX Yearly Current Assets VS Current LiabilitesNBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

NBTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.33%.
Looking at the last year, NBTX shows a very negative growth in Revenue. The Revenue has decreased by -80.24% in the last year.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.54%
Revenue 1Y (TTM)-80.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%168.36%

3.2 Future

Based on estimates for the next years, NBTX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.98% on average per year.
NBTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.57% yearly.
EPS Next Y48.11%
EPS Next 2Y34.49%
EPS Next 3Y28.66%
EPS Next 5Y26.98%
Revenue Next Year70.64%
Revenue Next 2Y91.53%
Revenue Next 3Y60.31%
Revenue Next 5Y37.57%

3.3 Evolution

NBTX Yearly Revenue VS EstimatesNBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 100M 200M 300M 400M 500M
NBTX Yearly EPS VS EstimatesNBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NBTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBTX Price Earnings VS Forward Price EarningsNBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBTX Per share dataNBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

NBTX's earnings are expected to grow with 28.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.49%
EPS Next 3Y28.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NBTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX SA - ADR

NASDAQ:NBTX (10/9/2025, 9:29:58 PM)

Premarket: 28.36 -1.55 (-5.18%)

29.91

+2.61 (+9.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-30 2025-09-30
Earnings (Next)11-10 2025-11-10
Inst Owners26.36%
Inst Owner Change0%
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap1.44B
Analysts86.67
Price Target14.71 (-50.82%)
Short Float %0.03%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.09%
PT rev (3m)15.4%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)12.07%
EPS NY rev (3m)23.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)61.26%
Revenue NY rev (3m)76.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 173.56
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.17
BVpS-1.66
TBVpS-1.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.5%
Cap/Sales 7.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -9.02
F-Score1
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.54%
EPS Next Y48.11%
EPS Next 2Y34.49%
EPS Next 3Y28.66%
EPS Next 5Y26.98%
Revenue 1Y (TTM)-80.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%168.36%
Revenue Next Year70.64%
Revenue Next 2Y91.53%
Revenue Next 3Y60.31%
Revenue Next 5Y37.57%
EBIT growth 1Y-75.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.1%
EBIT Next 3Y37.5%
EBIT Next 5Y36.1%
FCF growth 1Y14.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.56%
OCF growth 3YN/A
OCF growth 5YN/A